For a 50‑year‑old man with erectile dysfunction and no known comorbidities, should I obtain a hemoglobin A1c, a fasting lipid panel, or LH and FSH levels?

Obtain Hemoglobin A1c and Lipid Panel

For a 50-year-old man presenting with erectile dysfunction and no known comorbidities, you should obtain a hemoglobin A1c and fasting lipid panel, but not LH and FSH levels. 1

Rationale for Metabolic Screening

Erectile dysfunction is fundamentally a vascular disorder that serves as an early warning sign for cardiovascular disease—symptoms of ED typically appear approximately three years before coronary artery disease manifests 2. This makes ED a critical opportunity for cardiovascular risk stratification.

The British Society for Sexual Medicine explicitly states that measurement of fasting serum glucose and lipid profile should be considered mandatory in all newly presenting ED patients 1. This recommendation is supported by compelling epidemiological data:

• 52.9% of ED patients have elevated hemoglobin A1c
• 48.4% have abnormal total serum cholesterol levels 3

These prevalence rates are remarkably high and justify universal screening. The 2021 EAU guidelines similarly emphasize screening for cardiovascular and endocrine risk factors in all newly presenting ED patients 4.

Why Not Routine Hormonal Testing

The American College of Physicians explicitly states there is insufficient evidence to recommend for or against routine hormonal blood tests (including LH and FSH) in ED management 5. This represents a critical distinction: while testosterone measurement may be considered in select cases, routine LH and FSH testing lacks supporting evidence.

The prevalence data supports this approach:

• Only 18.7% of ED patients have low testosterone
• Only 4.6% have elevated prolactin
• 14.6% have abnormal LH levels 3

These rates are substantially lower than the metabolic abnormalities, making universal hormonal screening less cost-effective.

When to Consider Hormonal Testing

Reserve morning total testosterone measurement for patients with:

• Symptoms suggesting hypogonadism (decreased libido, fatigue, loss of muscle mass)
• Failed response to PDE-5 inhibitors
• Age >50 years with multiple risk factors 1, 4

LH and FSH should only be obtained after documenting low testosterone on two separate morning measurements, to differentiate primary from secondary hypogonadism 6.

Clinical Pitfalls to Avoid

• Do not skip metabolic screening even in younger patients—elevated LDL, blood glucose, and creatinine are independent risk factors for ED in men as young as 20-40 years 7
• Do not order comprehensive hormonal panels reflexively—this increases costs without improving outcomes in most patients
• Do not ignore the lipid panel results—isolated postprandial dyslipidemia (which may be missed on fasting tests) is independently associated with ED prevalence and severity comparable to chronic dyslipidemia 8

Summary Algorithm

For a 50-year-old man with new-onset ED and no known comorbidities:

1. Order immediately: Hemoglobin A1c and fasting lipid panel
2. Consider adding: Morning total testosterone if symptoms suggest hypogonadism or patient is >50 years
3. Do not order routinely: LH, FSH, prolactin, or TSH unless specific clinical indicators are present
4. Initiate PDE-5 inhibitor therapy while awaiting results, unless contraindicated 5
5. Address any identified metabolic abnormalities aggressively—lifestyle modification and pharmacologic management of diabetes and dyslipidemia may improve ED independent of specific ED treatments